187 related articles for article (PubMed ID: 24335926)
1. Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.
Pisanu ME; Ricci A; Paris L; Surrentino E; Liliac L; Bagnoli M; Canevari S; Mezzanzanica D; Podo F; Iorio E; Canese R
Br J Cancer; 2014 Feb; 110(3):625-35. PubMed ID: 24335926
[TBL] [Abstract][Full Text] [Related]
2. Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.
Canese R; Palombelli G; Chirico M; Sestili P; Bagnoli M; Canevari S; Mezzanzanica D; Podo F; Iorio E
NMR Biomed; 2019 Oct; 32(10):e4016. PubMed ID: 30375088
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
4. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
[TBL] [Abstract][Full Text] [Related]
5. SV40 T/t-common polypeptide enhances the sensitivity of HER2-overexpressing human cancer cells to anticancer drugs cisplatin and doxorubicin.
Hsueh SP; Du JL; Hsu WB; Fang CA; Liu H; Wang WB
Cancer Lett; 2012 Nov; 324(1):48-57. PubMed ID: 22546288
[TBL] [Abstract][Full Text] [Related]
6. Impact of Cold Ischemia on the Stability of
Ricci A; Dugo M; Pisanu ME; De Cecco L; Raspagliesi F; Valeri B; Veneroni S; Chirico M; Palombelli G; Daidone MG; Podo F; Canese R; Mezzanzanica D; Bagnoli M; Iorio E
J Proteome Res; 2024 Jan; 23(1):483-493. PubMed ID: 38109371
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and
Paris L; Podo F; Spadaro F; Abalsamo L; Pisanu ME; Ricci A; Cecchetti S; Altabella L; Buoncervello M; Lozneanu L; Bagnoli M; Ramoni C; Canevari S; Mezzanzanica D; Iorio E; Canese R
Oncotarget; 2017 Aug; 8(33):55022-55038. PubMed ID: 28903399
[TBL] [Abstract][Full Text] [Related]
8. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
9. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response.
Klostergaard J; Auzenne E; Ghosh S; Farquhar D; Rivera B; Price RE
Int J Gynecol Cancer; 2006; 16 Suppl 1():111-7. PubMed ID: 16515577
[TBL] [Abstract][Full Text] [Related]
11. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
[No Abstract] [Full Text] [Related]
12. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.
Menderes G; Bonazzoli E; Bellone S; Black JD; Lopez S; Pettinella F; Masserdotti A; Zammataro L; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Med Oncol; 2017 May; 34(5):91. PubMed ID: 28397106
[TBL] [Abstract][Full Text] [Related]
13. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
Liu YK; Jia YJ; Liu SH; Ma J
Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
[TBL] [Abstract][Full Text] [Related]
14. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine reverses chemoresistance via upregulation of p21
Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW
Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
17. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
18. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
[TBL] [Abstract][Full Text] [Related]
20. An Evaluation of HER2-Positive Ovarian Carcinoma Xenografts: From a Novel Therapy to a Noninvasive Monitoring Method.
Hong Z; Mao X; You J; Liu Z; Shi Y
Cancer Biother Radiopharm; 2018 Nov; 33(9):411-419. PubMed ID: 30052070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
